FDA Accepts Correvio’s Refiling of Brinavess NDAAntiarrhythmic drugs, FDA, FDA/Regulatory, NDA Resubmission, PDUFA, Recent onset atrial fibrillationCorrevio Pharma Corp. announced that the U.S. Food and Drug Administration accepted for review the resubmitted New Drug Application (NDA) for the antiarrhythmic drug Brinavess. Read more July 25, 2019/by PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 PR Newswire https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png PR Newswire2019-07-25 07:00:532019-07-25 13:26:33FDA Accepts Correvio’s Refiling of Brinavess NDA